NCARDIA
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive human cellular assay systems for safety and efficacy testing of drug candidates as well as enhance cardiovascular and neural drug screening, enabling researchers to bring predictive human disease biology and accelerate drug discovery.
NCARDIA
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2010-01-01
Address:
Leiden, Zuid-Holland, The Netherlands
Country:
The Netherlands
Website Url:
http://www.ncardia.com
Total Employee:
11+
Status:
Active
Contact:
(310) 713-3222
Email Addresses:
[email protected]
Total Funding:
83.72 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics Global Site Tag Mobile Non Scaleable Content Nginx
Similar Organizations
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
KINICITI
KINICITI investment in Venture Round - Ncardia
Vesalius Biocapital Partners
Vesalius Biocapital Partners investment in Series B - Ncardia
Sambrinvest
Sambrinvest investment in Series B - Ncardia
InnovationQuarter
InnovationQuarter investment in Series B - Ncardia
S.R.I.W.
S.R.I.W. investment in Series B - Ncardia
SFPI-FPIM
SFPI-FPIM investment in Series B - Ncardia
Epimède SA
Epimède SA investment in Series B - Ncardia
SFPI-FPIM
SFPI-FPIM investment in Venture Round - Ncardia
Sambrinvest
Sambrinvest investment in Venture Round - Ncardia
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Ncardia
Key Employee Changes
| Date | New article |
|---|---|
| 2022-02-24 | Ncardia Appoints Andy Holt as Chief Commercial Officer |
Official Site Inspections
http://www.ncardia.com Semrush global rank: 4.52 M Semrush visits lastest month: 2.34 K
- Host name: 199.60.103.119
- IP address: 199.60.103.119
- Location: Canada
- Latitude: 43.6319
- Longitude: -79.3716
- Timezone: America/Toronto
More informations about "Ncardia"
About Ncardia
At Ncardia, we lean into advanced technology, so we can provide the right solutions: high-quality cells, relevant screening assays and robust iPSC differentiation processes for drug discovery …See details»
Ncardia
At Ncardia, we are pioneers in iPSC technology providing high-quality cells, relevant screening assays and robust iPSC differentiation processes, with an excellent customer service.See details»
The Team at Ncardia
He co-founded Pluriomics/Ncardia in 2011, and, as the inventor of its core technologies, has been instrumental in the establishment and growth of the organization. Stefan earned a MSc and …See details»
Ncardia - Crunchbase Company Profile & Funding
Ncardia is an Operator of a biotechnology company intended to expedite drug discovery and development process.The company uses hiPSC stem cell technology to develop predictive …See details»
Ncardia - LinkedIn
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America.See details»
Ncardia - Overview, News & Similar companies | ZoomInfo.com
Feb 24, 2022 Who is Ncardia. Founded in 2000 and headquartered in Belgium, Ncardia brings cell manufacturing and process development expertise to cell therapy by designing and …See details»
Ncardia - The Org
Ncardia is a drug discovery company and expert in human iPSC technology. We operate worldwide with facilities, offices and staff throughout Europe and North America. We work with …See details»
Ncardia Overview | SignalHire Company Profile
The position of the CEO is occupied by Stefan Braam. Its headquarters is located at Leiden, Other, NL. The number of employees ranges from 25 to 100. The annual revenue of Ncardia …See details»
Ncardia Company Profile - Office Locations, Competitors ... - Craft
Ncardia is a stem cell drug discovery and development company. The Company is focused on the development of fully functional human assay systems for use in drug discovery and …See details»
Ncardia - Company Profile - Tracxn
Nov 25, 2024 Ncardia, formed by the merger of Pluriomics and Axiogenesis in 2017, is a stem-cell based drug discovery and development services provider specializing in offering hiPSC …See details»
Ncardia - VentureRadar
Mar 5, 2018 Ncardia is built on the belief that stem cell technology will help bring better therapies to patients faster. Our goal is to enable biopharmaceutical companies in drug discovery and …See details»
Ncardia - Drug Target Review
Ncardia is a stem cell technology company focused on the cell therapy, drug discovery, and safety/tox markets. We believe that human stem cell biology will deliver superior therapies to …See details»
Ncardia - Products, Competitors, Financials, Employees, …
Ncardia is a company specializing in human induced pluripotent stem cell (iPSC) technology within the biopharmaceutical industry. The company provides iPSC-derived cell models, …See details»
Ncardia - Lifesciences @ Work
Ncardia is a full-stack human iPSC technology company operating worldwide with facilities, offices and staff in Belgium, the Netherlands, France and North America. Ncardia is built on the belief …See details»
Ncardia - Raised $77.4M Funding from 11 investors - Tracxn
Nov 30, 2024 List of Ncardia's institutional investors. Kiniciti, located in New York City (United States), made their first investment in Ncardia on Nov 16, 2021 in its Series C round.; …See details»
Unveiling Ncardia's Path to Innovation and Growth
Jul 5, 2024 How does Ncardia support drug and cell therapy developers? Ncardia bolster drug discovery by developing disease-relevant assays based on human iPSC technology, …See details»
Cell therapy weekly: Ncardia launches iPSC-based cell therapy ...
Apr 21, 2022 Ncardia launches Cellisticâ„¢, an iPSC cell therapy development and manufacturing organization. Ncardia (Gosselies, Belgium) have announced the launch of Cellisticâ„¢, a new …See details»
Our Approach - Ncardia
We live iPSC: At Ncardia, we’ve been pursuing and supporting iPSC innovations for more than a decade, collaborating with and/or licensing our iPSC technologies to up-and-coming drug …See details»
About us | Ncardia
We are a team of passionate people whose goal is to improve everyone's life through disruptive products.See details»
Press release: Ncardia Secures $60+ Million to Enhance and …
Nov 15, 2021 Gosselies, Belgium and New York, N.Y. (Nov. 16, 2021) Ncardia, a leader in developing stem cell-based solutions for drug discovery and cell therapy, announced that it …See details»